r In the rat nucleus of the solitary tract (NTS), activation of astrocytic proteinase-activated receptor 1 (PAR1) receptors leads to potentiation of neuronal synaptic activity by two mechanisms, one TRPV1-dependent and one TRPV1-independent.
Introduction
Besides providing metabolic and structural support for neurons, astrocytes also modulate neuronal activity, synaptic transmission, plasticity and critical physiological functions. Pioneering studies over the past two decades have given rise to the idea of a tripartite synapse in which astrocytes, in conjunction with pre-and postsynaptic elements, form a functional compartment for processing and integration of synaptic information (Araque et al. 1999) . Astrocytes express a host of neurotransmitter receptors and display calcium excitability in response to synaptic stimulation (Agulhon et al. 2008) . Accumulating evidence indicates that activation of astrocytic G-protein-coupled receptors (GPCRs) can modulate neuronal excitability and presynaptic neurotransmitter release (Perea et al. 2009 ).
The caudal nucleus of the solitary tract (NTS), a major hub of visceral sensory input, mediates the regulation of crucial homeostatic functions such as breathing, arterial pressure, gastric motility and food intake (Barnes et al. 2003; Alheid & McCrimmon, 2008; Hermann et al. 2009; Dean & Putnam, 2010; Huda et al. 2012; Kanoski et al. 2012 ). Light and electron microscopy studies show that astrocytic processes cover excitatory synapses in the NTS, suggesting they regulate neurotransmission (Chounlamountry & Kessler, 2011) . NTS astrocytes express AMPA receptors (McDougal et al. 2011 ) and participate in several important physiological responses such as glucose homeostasis (McDougal et al. 2013) . Recently, we proposed that NTS astrocytes modulate excitatory neurotransmission in a pH-dependent manner, which may allow them to regulate cardiorespiratory homeostasis (Huda et al. 2013) . NTS astrocytes respond to stimulation of afferent fibres in the solitary tract with an increase in intracellular calcium (McDougal et al. 2011) . Moreover, stimulating NTS astrocytes by activating proteinase-activated receptor 1 (PAR1), a GPCR (reviewed by Traynelis & Trejo, 2007) that, in the NTS, is expressed selectively in astrocytes, triggers an increase in neuronal calcium levels (Hermann et al. 2009; Vance et al. 2015) and potentiates excitatory synaptic transmission (Vance et al. 2015) . While NMDAR-mediated signalling was previously suggested to underlie the effect of astrocyte activation on neuronal synaptic transmission (Vance et al. 2015) , it remains unclear if additional mechanisms are also involved. Here, we describe a novel cellular mechanism underlying these effects. We show that activation of PAR1 receptors in acute slices increases presynaptic glutamate release onto NTS neurons via a TRPV1-dependent and a TRPV1-independent mechanism. The TRPV1-dependent mechanism depends on phospholipase C (PLC), the endocannabinoid membrane transporter, and anandamide transport and hydrolysis, but not on astrocytic intracellular calcium.
In vivo, the TRPV1-dependent, PAR1-mediated NTS activation potently modulates respiratory motor output.
Methods
All animals were handled in accordance with National Institutes of Health guidelines and all procedures were approved by the Northwestern University Animal Care and Use Committee.
Animals
Experiments were carried out on wild-type (WT) and male WT (Harlan) and TRPV1 −/− (Horizon discovery) Sprague-Dawley rats. The TRPV1 −/− rats contain a biallelic deletion of the TRPV1 gene. As a consequence, western blot analysis on brain homogenates fails to detect any TRPV1 protein and the animals show strongly reduced sensitivity to the hot plate test (https://www. horizondiscovery.com/trpv1-knockout-rat-tgrs5530).
Acute slice preparation
Brainstem slices were obtained from 14-to 25-day-old male WT and TRPV1
−/− Sprague-Dawley rats. Animals were deeply anaesthetized with isoflurane and then decapitated. The brainstem was quickly removed into ice-cold low Ca 2+ , high Mg 2+ artificial cerebrospinal fluid (ACSF; in mM: 125 NaCl, 25 NaHCO 3 , 2.5 KCl, 1.25 NaH 2 PO 4 , 25 glucose, 0.1 CaCl 2 and 7 MgCl 2 ) equilibrated with 95% O 2 and 5% CO 2 .
Transverse slices (275 μm) containing the NTS (from between ß925 and 400 μm caudal to the obex; i.e. the opening of the central canal into the 4 th ventricle) were cut using a vibrating blade microtome (Thermo Fisher Scientific, Waltham, MA, USA) and recordings were made in the NTS, medial to the solitary tract. Slices were stored in sucrose-based ACSF (in mM: 87 NaCl, 25 NaHCO 3 , 25 glucose, 75 sucrose, 2.5 KCl, 1.25 NaH 2 PO 4 , 0.1 CaCl 2 and 7 MgCl 2 ; equilibrated with 95% O 2 and 5% CO 2 ) for up to 30 min at 33-35°C after cutting and at room temperature thereafter until used for recordings.
Patch clamp recordings from neurons and glia
Slices were transferred to a recording chamber constantly superfused with regular bicarbonate-buffered ACSF (in mM: 125 NaCl, 2.5 KCl, 25 NaHCO 3 , 25 glucose, 2 CaCl 2 , 1 MgCl 2 , bubbled with 95% O 2 /5% CO 2 ) at 33-35°C. The bath temperature was controlled using a Warner TC-324B temperature control unit; the temperature probe was positioned half-way between the bath perfusion inlet and the suction, very close to the position of the recording pipette, to ensure the most reliable readout of the temperature. Recordings were made with an Axopatch 200B (Molecular Devices, Sunnyvale, CA, USA) and/or MultiClamp 700A (Molecular Devices) amplifier, digitized with a 1440A Digidata acquisition board (Molecular Devices), and displayed and saved on a digital computer with Clampex 10.2 software (Molecular Devices). Slices were visualized with an upright microscope (Olympus) with oblique infrared illumination and video microscopy using a digital camera (DVC). Patch pipettes were fabricated from borosilicate capillary tubes (Sutter Instrument Co., Novato, CA, USA: o.d., 1.5 mm; i.d., 0.86 mm) using a vertical puller (PC-10, Narishige, Narishige International USA, Amityville, NY, USA) and had tip resistances of 2-8 M when filled with working solution. Traces were filtered at 2 kHz or 10 kHz using the built-in filter and digitized at 5 and 20 kHz, for voltageand current-clamp recordings, respectively.
Voltage-clamp recordings of spontaneous excitatory postsynaptic currents (EPSCs) were made at −60 mV and in the presence of 50-100 μM picrotoxin and 1 μM strychnine to block GABAergic and glycinergic neurotransmission, respectively. These recordings were made using a CsCl-based internal solution (in mM: 140 CsCl, 2 MgCl 2 , 10 EGTA, 10 Hepes and 5 QX-314 (pH 7.3 with CsOH). Current-clamp recordings were made using a potassium gluconate-based internal solution (in mM: 130 potassium gluconate, 10 NaCl, 2 MgCl 2 , 10 EGTA and 10 Hepes, titrated to pH 7.3 with KOH) in the presence of blockers of fast inhibitory transmission. Series resistances were <25 M and were not compensated.
For glial recordings, in a first set of recordings, glial cells were visually identified by pre-incubation of the slices with the glia-selective marker sulforhodamine 101 (SR101; Nimmerjahn et al. 2004) . In all cases, the glial nature of the recorded cell was confirmed by their negative resting membrane potential, the typical symmetrical responses to injections of hyperpolarizing and depolarizing current steps and the inability to generate action potentials under any experimental condition (Huda et al. 2013) . After training on a few preparations it became possible to identify glia on the basis of size and morphology, and we discontinued using SR101.
The PAR1 agonist SFLLRN (R&D Systems, Minneapolis, MN, USA) was dissolved in Hepes-buffered ACSF (in mM: 138 NaCl, 2.5 KCl, 10 Hepes, 25 glucose, 2 CaCl 2 , 1 MgCl 2 , titrated to pH 7.4 with NaOH). SFLLRN was pressure applied (20-25 psi; 500 ms) using a Picospritzer II (General Valve Corp., Fairfield, NJ, USA) through puffer pipettes pulled from single barrel borosilicate glass tubing (Sutter Instrument Co.) and with tip resistances of ß4-6 M . The puffer was placed 50-100 μm from the patched neuron. Cells were allowed to recover for ß10 min before a subsequent challenge with SFLLRN. Drugs of interest were bath applied during this time. All pharmacological agents were tested on different slices.
Electrophysiological analysis
Electrophysiological data were analysed using Clampfit 10.2 software (Molecular Devices) and custom scripts written in MATLAB (The MathWorks Inc., Natick, MA, USA). For voltage-clamp recordings, traces were manually baseline corrected and synaptic events were automatically identified using a template search protocol; found events were visually inspected for accuracy and any spurious events were discarded. Events larger than 10 pA were found using custom MATLAB scripts and included in the analysis. The event start time was used to plot the frequency histograms of found events in 5 s bins (e.g. Fig. 4Aa ). Total number of events detected in a 30 s period preceding the SFLLRN application were used to calculate the baseline sEPSC count. Events occurring in a 30 s period starting 5 s following SFLLRN application were normalized to the average baseline count computed over all cells in the group to quantify the effect of PAR1 activation. For comparing drug effects, these normalized values were compared. Only slices where at least one neuron responded were used to determine the percentage of neurons responding to SFLLRN.
Calcium recordings and analysis from astrocytes
The procedure for bulk loading brainstem slices with fura-2-AM calcium indicator was modified from Ikegaya et al. (2005) . Briefly, 50 μg of fura-2-AM was dissolved in 12 μl dimethyl sulfoxide (DMSO) solution containing 3.3% (w/v) pluronic F-127 (Invitrogen, Carlsbad, CA, USA) and sonicated for 25-30 min. Slices were placed in a 35 × 10 mm Petri dish with 2 ml of regular ACSF equilibrated with 95% O 2 and 5% CO 2 . The dye solution was added to the ACSF (final concentration 25 μM). Slices were incubated in the solution at 35°C for up to 1 h, then transferred to the storage chamber and stored in sucrose-ACSF at room temperature for at least 1 h to allow for dye de-esterification before they were used for calcium recordings.
Calcium imaging was performed using an epifluorescence microscope equipped with a ×60 objective and a mercury lamp as light source (Olympus). Fura-2 was excited alternatingly at wavelengths of 340 nm and 380 nm using optical filters (Chroma) loaded into a Lambda 10-2 filter wheel (Sutter Instrument Co.). A dichroic mirror with edge at 409 nm (Semrock, Semrock Inc, Rochester, NY, USA) was used to direct excitation light to the sample and emitted light to the imaging camera (Rolera EM-C 2 , Q-Imaging, Surrey, BC, Canada). The camera system and the filter wheel were controlled by NIS-Elements software (Nikon). SFLLRN (1 mM) was puff applied (ß20 psi, 500 ms pulse) through a patch pipette to visually identified astrocytes that showed fura-2 labelling. None of the J Physiol 596.3 fura-2-labelled cells visually identified as astrocytes showed action potentials in response to positive current injections during patch clamp recordings, confirming their astrocytic phenotype (data not shown).
Images were acquired at 1 Hz and raw fluorescence data were extracted from NIS-Elements software (Nikon) and ImageJ (NIH). Regions of interest (ROIs) were placed over astrocytes and the ratio of fluorescence emitted by the excitation of fura-2 at 340 nm and 380 nm was calculated. Data were analysed in MATLAB using custom scripts. The ratio at each time point was normalized to the average of a 20-30 s baseline period preceding agonist application. To determine if an astrocyte showed a significant response, the normalized baseline was compared with a 20 s period following SFLLRN application using Student's t test. Moreover, to avoid inclusion of spurious events, only cells exhibiting fluorescence changes greater than 4 standard deviations of the baseline were considered responsive. To quantify the effect of SFLLRN application on responsive astrocytes, we compared the maximum fluorescence value observed during the 20 s baseline period with the maximum value recorded 20 s after the application.
All chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA), unless noted otherwise. D-(-)-2-Amino-5-phosphonopentanoic acid (D-AP5), picrotoxin, 6,7-dinitroquinoxaline-2,3-dione disodium salt (DNQX), U73122, capsazepine, thapsigargin, JNJ1661010 and HC-030031 were purchased from Tocris (R&D Systems). Drugs were dissolved in stock solutions and working solutions were prepared daily.
In vivo measurements and procedures
Injection of retrograde tracers into the rostral ventral respiratory group. Adult male rats (250-450 g) were anaesthetized with isoflurane (5% induction, 2.5-3% maintenance). Adequacy of anaesthesia was evaluated at least every 15 min by assessing any withdrawal reflex or changes in heart rate or respiration rate in response to a noxious paw pinch. Transcutaneous needle electrodes were placed over the caudal ribcage to record ECG and respiratory EMG as a marker of the inspiratory phase of breathing. Rectal temperature was monitored and maintained at 36.5-38.5°C by means of a thermistor-controlled heating pad and heat lamp. Arterial oxygen saturation was monitored throughout the experiment via a pulse oximeter (Mouse Ox, Starr Life Sciences, Oakmont, PA, USA). Rats were placed in a stereotaxic headholder. As previously described (Monnier et al. 2003) , a midline incision was made in the dorsal aspect of the neck, the underlying muscles separated and a small amount of the caudal aspect of the occipital bone removed to expose the fourth ventricle and calamus scriptorius. Single barrel glass micropipettes (1.2 mm o.d., 0.68 mm i.d.) suitable for both extracellular recording and tracer injection were pulled and broken to an external tip diameter of 10-12 μm. Pipettes were filled with a solution containing 20% rhodamine-impregnated latex beads (LumaFluor Inc. New City, NY, USA) suspended in 0.9% NaCl. A silver wire was introduced into the pipette for extracellular recording. For pressure injection, polyethylene tubing was sealed over the pipette and connected to a regulated, solenoid-valve-controlled pressure source. Injection volumes were monitored using a compound microscope equipped with a fine reticule. Using a dissecting microscope, the tip of the electrode was positioned on the dorsal surface of the brainstem at the level of the calamus scriptorius. This point defined a relative zero for rostrocaudal and lateral displacements.
Extracellular recording of respiratory neuron activity was used to identify proper positioning of the electrode within the rostral ventral respiratory group (rVRG). If respiratory activity was not observed, the electrode was withdrawn from the brainstem and moved 200 μm medial or lateral to the preceding electrode track and an additional penetration initiated. The pipette was advanced to the centre of the respiratory neuronal population as verified in real time by recording spontaneous respiratory multi-unit activity (not shown) and post hoc by anatomical visualization of the injection site (see Fig. 12 ) and 30-50 nl of tracer solution was slowly injected at this site. Following the tracer injection, a minimum of 15 min was allowed prior to removal of the pipette to reduce the tendency to aspirate the tracer dorsally along the electrode tract. The non-steroidal anti-inflammatory drug meloxicam (1 mg kg −1 , S.C.) was then administered and the surgical wound sutured. Anaesthesia was discontinued and following recovery of the righting responses, the opiate analgesic buprenorphin was administered (0.03 mg kg −1 , S.C.). Buprenorphin was repeated 12 h post-operatively and meloxicam at 24 h.
Recording of breathing parameters and drug delivery
to the NTS. Following sufficient time for retrograde transport (7 days) the animals were again anaesthetized with isoflurane (5% induction, 2.5-3% maintenance). A dorsal midline incision was made in the neck and the dorsal surface of the brainstem exposed. Adequacy of anaesthesia was assessed at least every 15 min noting any changes in heart rate, arterial pressure, or respiratory rate in response to a noxious paw pinch. A femoral vein and artery were catheterized for intravenous drug delivery and monitoring arterial pressure, respectively. Rats were tracheotomized, bilaterally vagotomized in the neck and mechanically ventilated with 50% O 2 , balance N 2 (70 breaths min −1 ; tidal volume 2.5-3 ml). Paralysis was instituted with succinyl choline chloride (2 mg kg
and maintained with an intravenous infusion (0.5 ml h −1 ) of lactated Ringer solution containing succinyl choline chloride (10 mg ml −1 ). Arterial oxygen saturation was continuously monitored via a pulse oximeter (see above). Expired P CO 2 was continuously measured with an infrared analyser (Datex 223, Medtronic, Minneapolis, MN, USA) modified to minimize dead space. End-tidal P CO 2 was adjusted by adding CO 2 to the inspired gas mixture. Rectal temperature was monitored and maintained between 37.5 and 38.5°C by means of a thermistor-controlled heating lamp.
Rats were placed in a stereotaxic frame with the head ventroflexed such that the dorsal brainstem was approximately horizontal. A phrenic nerve was isolated using a dorsal approach in the neck, placed on a bipolar silver wire electrode and bathed in mineral oil for recording respiratory motor activity. Nerve activities were amplified, filtered (band pass 300 Hz to 10 kHz), full-wave rectified, and integrated (Paynter filter; time constant 15 ms). An occipital craniotomy was performed and the dura and arachnoid membranes removed to expose the dorsal surface of the brainstem at the level of the area postrema.
A single barrel micropipette (10-15 μm o.d.) containing either SFLLRN (1 mM in 0.9% NaCl) or 0.9% NaCl was positioned within a region extending 300-500 μm lateral to the midline, and ±300 μm rostrocaudal to calamus scriptorius (i.e. a similar region to that explored in vitro). The pipette was connected to a pressure source via a solenoid valve, advanced 300-700 μm ventral to the dorsal surface and 50 nl of either SFLLRN or 0.9% NaCl injected slowly. Injection volumes were directly monitored using a compound microscope equipped with a fine reticule.
Histological analysis. Two hours after injection of SFLLRN or NaCl, isoflurane was increased to 5% and rats were perfused transcardially with 4% formaldehyde in 0.1 M phosphate buffer.
The brains were dissected from the skull and cryoprotected in successive passes of 10, 20, and 30% sucrose in phosphate buffered saline. Cryoprotected brains were sectioned serially at 30 μm in coronal planes on a vibrating blade microtome. Alternate sections were saved and transferred serially to multiwell tissue culture plates containing 0.1 M PBS. Prior to antibody staining, endogenous peroxidases were blocked by incubating sections in 10% methanol, 0.3% H 2 O 2 , 1× Tris-buffered saline (TBS) for 30 min. After thorough rinsing in buffer, sections were blocked with 5% normal donkey serum, 1% bovine serum albumin (BSA), 0.2% Triton X-100) in TBS. Incubation with primary antibody (anti-cFOS, 1:1,000 to 1:2,000, Millipore, Billerica, MA, USA) took place for approximately 72 h at 4°C. Sections were subsequently incubated with a biotinylated donkey anti-rabbit antibody (1:200, GE Healthcare) for 1 h. After four to six rinses in 1× TBS, sections were incubated in ABC Elite (Vector Laboratories, Burlingame, CA, USA) for 1 h and rinsed 4-6 times in TBS. After extensive washing with 1× TBS buffer, samples were rinsed an additional two times prior to the addition of DAB (0.05% 3,3-diaminobenzidine•HCl-0.00525% H 2 O 2 in 1× PBS). The reaction was stopped by washing the sections extensively in 1× PBS. Sections were mounted on gelatin-subbed slides, coverslipped with Entallan mounting media (EMS, Hatfield, PA, USA) and observed with a Nikon Eclipse E800 microscope.
For fluorescence staining, the antibody staining procedure was similar to that used for visualization with DAB, with minor modifications. Sections were incubated directly with blocking buffer as above, but normal goat serum was substituted for normal donkey serum. Subsequent to washing after primary antibody incubation, sections were incubated in goat anti-rabbit AlexaFluor R 488 (Jackson ImmunoResearch Laboratories, West Grove, PA, USA, 1:450, or Invitrogen, 1:600) for approximately 1 h. After extensive washing, sections were mounted on gelatin-subbed slides and coverslipped in ProLong Diamond (Invitrogen, S36963) and once cured were observed with a Nikon Eclipse E800 microscope.
For control experiments, sections were incubated without primary antibodies and no staining was detected.
Statistical analysis. Fos-positive cells and rhodamine beads-Fos double labelled cells were counted at ×40 magnification. The number of Fos positive cells per section was compared in NTS (+0.5 to −0.5 mm to obex). The counts were performed on five sections from each of three WT and three TRPV1 −/− rats (30 sections in total). Ex vivo cellular data were analysed using Student's paired or unpaired, two-tailed t test (using Microsoft Excel or code written in Matlab) and are presented as means ± SEM. The sample size reported for each experiment represents the number of cells that were tested. The samples of each group were collected from at least three different animals. The only exception was for the data concerning the effect of SFLLRN application on AP firing (Fig. 1B and D) , which was obtained from two animals.
All recordings that were deemed of sufficient quality (including stable baseline sEPSC frequency) during the data acquisition were analysed and included in the final data sets. To reliably test the effect of pharmacological manipulations on SFLLRN-induced increases in sEPSC frequency, we excluded cells with baseline sEPSC frequency greater than 10 times the mean baseline frequency of its cohort, leading to exclusion of one cell from analysis. Comparisons between proportions were performed using the chi-square test.
In vivo, the effect of SFLLRN vs. saline on phrenic motor activity was compared using a two-way ANOVA with main factors of treatment (SFLLRN and saline) and time. Significant differences were followed up using the Bonferroni procedure for multiple comparisons. Statistical significance was assessed in all cases at a P value <0.05 (indicated in figures by * ).
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Results

PAR1-mediated activation of astrocytes modulates excitatory synaptic transmission
To selectively activate NTS astrocytes, we took advantage of the fact that in the NTS the GPCR PAR1 is expressed in astrocytes, but not in neurons (Hermann et al. 2009; Vance et al. 2015) . Since PAR1 is a G q -linked GPCR that leads to calcium release from internal stores (Lee et al. 2007; Shigetomi et al. 2008) , we bulk-loaded brainstem slices with fura-2-AM to monitor the physiological effect of PAR1-receptor activation on visually identified astrocytes. As expected from previous studies on NTS astrocytes (Hermann et al. 2009 ), puff applications (ß20 psi, 500 ms) of the PAR1 receptor-selective agonist peptide (SFLLRN, 1 mM) increased intracellular calcium in 25 of 40 astrocytes tested (9.3 ± 0.01% increase in the fura-2 ratio at the peak of the response; Fig. 1A ; P = 1.1 × 10 −9 for responsive cells; paired t test). The existence of glial responders and non-responders is in agreement with the non-homogeneous pattern of PAR1 staining of glia in this area (Hermann et al. 2009 ). In addition to the effect on glia, current clamp recordings in NTS neurons showed that SFLLRN application enhanced action potential firing (Fig. 1B and D) , suggesting that astrocyte activation was promptly relayed onto neurons. Activation of G q -linked GPCRs in astrocytes has been previously shown to modulate synaptic transmission (Halassa & Haydon, 2010) . To test if PAR1-mediated astrocyte activation modulates excitatory transmission to NTS neurons, we recorded spontaneous excitatory postsynaptic currents (sEPSCs) in the presence of blockers of fast inhibitory transmission (100 μM picrotoxin and 1 μM strychnine). In a large subset of patched neurons (ß60%), puff application of SFLLRN (1 mM) in the vicinity (50-100 μm) led to a ß4-fold increase in the frequency of sEPSCs (5.5 ± 0.7 vs. 23.6 ± 2.9 Hz in preand post-SFLLRN, respectively; n = 39, P = 7.5 × 10 −8 , paired t test, Fig. 1C and D) , without affecting their amplitudes (−26.5 ± 1.8 vs. −28.2 ± 1.7 pA in preand post-SFLLRN, respectively; n = 39, P = 0.253; not shown). These experiments also revealed that not all NTS neurons responded to SFLLRN application, suggesting the existence of two classes of neurons defined as responders and non-responders. In responder neurons, PAR1 activation increases synaptic excitability by inducing presynaptic glutamate release without apparent effects on the function of postsynaptic receptors. Consistent with this hypothesis, PAR1 activation increased the frequency of miniature EPSCs (mEPSCs) recorded in the presence of 500 nM tetrodotoxin (from 3.1 ± 1.1 to 12 ± 4 Hz following SFLLRN application; n = 6, P = 0.042, paired t test; Fig. 2 ), but had no effect on their amplitudes (−27.1 ± 3 vs. −25.3 ± 3.3 pA; n = 6 from 4 different rats). Since the potentiation was not observed in all neurons, all subsequent pharmacology experiments were performed only in responsive cells.
TRPV1 receptors contribute to PAR1-mediated modulation of synaptic activity
Next, we determined the mechanism by which PAR1 activation regulates synaptic transmission in the NTS. In order to obtain reliable pharmacological data, we first established the reproducibility of effects elicited by repeated SFLLRN applications. Slices puffed with SFLLRN were allowed to recover for ß10 min, followed by a second application. The sEPSC frequency potentiation (normalized to pre-SFLLRN baseline, see Methods) was slightly higher in response to the second application compared to the first application (133 ± 45% of the first application; n = 5, P = 0.032, paired t test; Fig. 3) , showing that at this time interval the response could be evoked without inducing apparent inactivation. For subsequent pharmacology experiments, slices were allowed to recover for at least 10 min between SFLLRN applications. A subpopulation of afferent terminals in the NTS expresses TRPV1 receptors, which are calcium-permeable channels gated by protons, temperature and vanilloids such as capsaicin (Caterina et al. 1997) , and potentiate presynaptic glutamate release Shoudai et al. 2010) . Since PAR1 activation increased synaptic input to NTS neurons ( Fig. 1C and D) , we hypothesized that the mechanism may involve TRPV1 receptors. To investigate this possibility, we first tested the effect of 50 μM ruthenium red (RuR), a non-selective blocker of TRPV channels (Clapham et al. 2001) . Bath application of RuR significantly attenuated the potentiation of sEPSC frequency, as compared to control (post-SFLLRN potentiation was 798 ± 179% in control, vs. 240 ± 73%, in RuR; n = 5, P = 0.029, paired t test; Fig. 4A ). In addition to blocking TRPV1 receptors, RuR also modulates the activity of other ion channels (Ma, 1993; Clapham et al. 2001; Czirják & Enyedi, 2002) , including TRPA1 channels, which also modulate presynaptic function in the NTS (Sun et al. 2009 ). However, TRPA1 channels are unlikely to make a significant contribution to the PAR1 effect in the NTS as bath application of HC-030031, a specific antagonist of TRPA1 channels, had no effect on the potentiation (post-SFLLRN increase in sEPSC frequency was 318 ± 62% in control vs. 411 ± 65% in HC-030031; n = 4, P = 0.25; paired t test; not shown). To confirm the involvement of TRPV1 channels, we tested the effect of two TRPV1 antagonists, capsazepine (CPZ, Szallasi et al. 2007) and SB366791 (Gunthorpe et al. 2004) . Bath application of 20 μM CPZ significantly inhibited the SFLLRN-induced increase in sEPSC frequency (665 ± 151% vs. 257 ± 73% post-SFLLRN increase in sEPSC frequency in control and CPZ, respectively; 8 cells, P = 0.0017, paired t test; Fig. 4B ), supporting the hypothesis that TRPV1 receptors are necessary for the stimulatory effect of SFLLRN. The potent and selective TRPV1 blocker SB366791 also caused a substantial reduction of the SFLLRN-induced effect ( Fig. 5A-D) ; the SFLLRN-induced frequency increase was 351 ± 55% in control conditions and 152 ± 28% in the presence of SB366791 (9 cells; P = 0.011, paired t test; Fig. 5D ), confirming that TRPV1 channels mediate a large fraction of the PAR1 activated response.
Phospholipase C signalling is required for the stimulatory effect of PAR1 activation on excitatory synaptic transmission
What links PAR1 activation in astrocytes to a TRPV1 receptor-dependent facilitation of presynaptic glutamate release? Since elevation of intracellular calcium in astrocytes has been proposed to modulate synaptic transmission in the hippocampus (Kang et al. 1998; Fiacco & McCarthy, 2006) and neocortex (Schummers et al. 2008; Min & Nevian, 2012) , we sought to determine whether the SFLLRN-induced increase in astrocytic calcium is related to the observed effect on synaptic transmission in the NTS. Calcium release from internal stores is a prominent route by which increases in intracellular calcium occur in astrocytes (Agulhon et al. 2008 ; but see Shigetomi et al. 2012) . Using calcium imaging with the indicator fura-2, we found that thapsigargin, which depletes internal calcium stores by blocking the endoplasmic reticulum Ca 2+ -ATPase (Treiman et al. 1998 the somatically measured PAR1-mediated increases in astrocytic intracellular calcium (in vehicle, 22 out of 26 astrocytes exhibited a somatic calcium response, as opposed to 0 out of 16 in the presence of 5 μM thapsigargin; Fig. 6A ). Next, we tested the effect of thapsigargin on SFLLRN-induced potentiation of sEPSC frequency. Bath application of thapsigargin slightly reduced the baseline frequency of sEPSCs (2.4 ± 0.5 vs. 1.7 ± 0.6 Hz in vehicle and thapsigargin, respectively; n = 4, P = 0.023; paired t test; not shown), but, surprisingly, it had no effect on SFLLRN-induced potentiation of sEPSC frequency in neurons (327 ± 72% vs. 301 ± 73% in DMSO vehicle and thapsigargin, respectively; n = 4, P = 0.83, paired t test; Fig. 6B ), suggesting that this potentiation is independent of somatic calcium elevations in astrocytes.
In the cascade of intracellular signalling events triggered by the stimulation of PAR1 receptors, calcium release from internal stores is downstream of PLC activation (Hermann et al. 2009 ). Therefore, a parallel signalling pathway triggered by PLC activation in astrocytes may be able to modulate presynaptic TRPV1 receptors independently of calcium level. In agreement with this hypothesis, we found that U73122 (5 μM), a PLC inhibitor, substantially attenuated the SFLLRN-induced increase in sEPSC frequency (290 ± 70% in DMSO vehicle vs. 138 ± 50% in U73122; n = 5, P = 0.025, paired t test; Fig. 7A ).
PAR1-mediated activation of presynaptic TRPV1 receptors is modulated by endocannabinoid membrane transporter
The results presented thus far suggest that the PAR1-mediated activation of astrocytes recruits PLC signalling, which leads to a TRPV1-dependent increase in presynaptic glutamate release. In addition to being activated by physical stimuli like protons and temperature, TRPV1 receptors are also gated by endogenous endocannabinoid-like lipids such as N-arachidonoyldopamine (NADA) and anandamide (Premkumar et al. 2004; Puente et al. 2011) . Interestingly, several studies indicate that in neurons, activation of the PLC pathway through metabotropic glutamate receptors (mGluRs) leads to endocannabinoid synthesis independently of increases in intracellular calcium (Maejima et al. 2001; Varma et al. 2001; Chevaleyre & Castillo, 2003; Azad et al. 2004; Hashimotodani et al. 2007; Kano et al. 2009 ). Similar to mGluRs, PAR1 receptors also couple with G q/11 (McCoy et al. 2012) , raising the possibility that a related mechanism may be at play in astrocytes. Hence, we hypothesized that PLC activation in astrocytes via PAR1 receptors leads to the release of an endocannabinoid-like endovanilloid messenger that modulates the activity of presynaptic TRPV1 receptors. This idea is supported by the finding that cultured astrocytes release endocannabinoids in response to activation of ionotropic and metabotropic receptors (Walter et al. 2002 (Walter et al. , 2004 . Moreover, exogenously applied NADA was recently shown to potentiate spontaneous glutamate release onto NTS neurons via an action on presynaptic TRPV1 receptors (Fawley et al. 2014) . Thus, endovanilloid lipids are promising candidates for the intercellular messenger generated by PAR1 activation.
To test this hypothesis, we took advantage of the fact that the TRPV1 ligand binding site is intracellular (Jordt & Julius, 2002) and, therefore, the endovanilloid molecules produced by astrocytes would have to traverse the presynaptic membrane to activate TRPV1 channels. Several studies have demonstrated that the action of exogenously applied endovanilloids on TRPV1 receptors depends on the endocannabinoid membrane transporter (EMT), which facilitates the intracellular uptake of endocannabinoid-like molecules (De Petrocellis et al. 2001; Marinelli et al. 2006; Starowicz et al. 2007 ). Hence, we tested the effect of OMDM1, a specific blocker of EMTs (Ortar et al. 2003) , on the SFLLRN-induced potentiation of glutamate release. To this end, we puffed SFLLRN in control bath or during application of OMDM1. Consistent with the hypothesis that PAR1 activation leads to the production of endovanilloids by astrocytes, OMDM1 significantly reduced the potentiation of sEPSC frequency (377 ± 156% vs. 186 ± 104% in vehicle and OMDM1, respectively; n = 8, P = 0.027, paired t test; Fig. 7B ). Thus, these experiments suggest a new glia-neuron interaction mechanism that appears to use endovanilloids as the gliotransmitter. In the NTS, activation of astrocytic PAR1 receptor recruits PLC signalling, resulting in endovanilloid release. EMT transporters translocate the endovanilloid molecules into the presynaptic terminal, where they gate TRPV1 receptors and lead to an increase in the release of glutamate (Fig. 8) .
Recordings in slices from TRPV1
−/− rats reveal two independent PAR1 activated mechanisms
While the experiments presented so far point to TRPV1 receptors as the effector of the PAR1-dependent modulation of glutamatergic synaptic currents in NTS neurons, it is unclear why TRPV1 antagonists only cause a partial block of the response. Further analysis of the data revealed that while TRPV1 antagonists caused a robust block in some responder neurons, these drugs caused no detectable effect on other responder neurons ( Fig. 9A  and C) . Thus, to further support our conclusion that activation of TRPV1 is necessary for the neuronal response to activation of astrocytic PAR1, we performed recordings in slices from TRPV1 −/− rats (Fig. 9B) . The overall probability of recording a response to SFLLRN application was significantly decreased in these slices, but some cells still responded to SFLLRN (27% responders vs. 62% in WT animals; n = 25 and 29, respectively; P = 0.012, chi-square test; Fig. 9C ), thus suggesting that in the rat, NTS activation of astrocytic PAR1 receptors exerts its effects through two distinct signalling pathways, one requiring TRPV1 and the other TRPV1 independent. This conclusion is also supported by the observation that not all the cells tested responded to block by SB366791 (see Fig. 5D ).
Effects of activation of NTS PAR1 receptor on breathing
The detection, albeit infrequent, of a PAR1 initiated response in NTS slices from TRPV1 −/− rats raised the question of the physiological relevance of the TRPV1-mediated response we observed ex vivo. NTS neurons are key contributors to the reflex control of breathing (Alheid et al. 2011) , and we reasoned that if the TRPV1-dependent modulation of NTS excitability has physiological relevance in intact animals, it may modulate breathing. To address this critical question, we performed in vivo recordings to test the effect of NTS SFLLRN injection on breathing in eight WT and four TRPV1 −/− anaesthetized rats. In WT rats, NTS SFLLRN injection significantly reduced respiratory motor output (F = 13.82254; P = 0.000425; two-way ANOVA) by reducing the peak amplitude of the integrated phrenic nerve activity (ß30% 7 min after injection) when compared with saline-injected control rats, without significant effects on respiratory frequency; Fig. 10) . Importantly, no change in either the peak amplitude of integrated phrenic nerve activity (P = 0.978; one-way ANOVA; Fig. 11 ) or respiratory frequency (not shown) was detectable when SFLLRN was injected into the NTS of four TRPV1 −/− rats, confirming that TRPV1 channels are a critical component of the pathway triggered by PAR1 activation in the NTS of WT rats. Thus, these in vivo experiments confirmed both the physiological relevance of this pathway and the critical involvement of TRPV1 channels.
To determine whether NTS neurons responding to PAR1 activation project directly to the rVRG the principal premotor brainstem area controlling inspiratory motor output, we retrogradely labelled rVRG-projecting NTS neurons by injecting fluorescent latex beads into the rVRG. Seven days after tracer injection, we injected the PAR1 agonist SFLLRN (50 nl, 2 h before perfusion) into the NTS and transcardially perfused the animals. Sections of the NTS were then stained for cFOS to identify neurons activated by SFLLRN and to establish whether cFOS co-localizes in neurons with retrogradely transported beads, indicating a direct projection of these NTS neurons to the rVRG region. Figure 12 shows that in the ipsilateral NTS, ß14% of all the cFOS stained neurons also contained beads (n = 15 sections from 3 rats), thus supporting the idea that a fraction of the NTS neurons that are driven in response to astrocytic PAR1 activation directly project to the premotor areas that regulate the breathing motor output.
Discussion
We found that a PAR1 activation-induced increase in presynaptic glutamate release in the NTS is dependent on PLC, endocannabinoid membrane transporters, and TRPV1 channels. This suggests that the mechanism linking PAR1-induced astrocyte activity to modulation of excitatory neurotransmission in the NTS involves the possible mobilization of an endovanilloid molecule in response to activation of astrocytic PLC (see model in Fig. 8 ). Our data show that while depletion of internal calcium stores via thapsigargin abolishes the PAR1-induced increase in astrocytic somatic calcium, it does not affect the PAR1-mediated modulation of synaptic transmission. While we cannot completely rule out the possibility that some type of calcium signalling persists at fine astrocytic processes even in the presence of thapsigargin and may contribute to the PAR1 effect, our results are supported by previous findings from knockout mice lacking the astrocyte-specific IP 3 R2. Even though these mice lack calcium release from internal stores in astrocytes, there is no effect on synaptic transmission in the hippocampus or on a battery of behavioural tests (Petravicz et al. 2014) . Further support for the hypothesis that astrocytic calcium is not critical in this process is provided by our finding that TRPA1 receptors, which are a major source of calcium influx at astrocytic processes (Shigetomi et al. 2011) , are not necessary for the PAR1-mediated astrocytic activation. PAR1 activation recruits several intracellular messengers in addition to calcium signalling (Flynn & Buret, 2004) . Hence, the most conservative explanation of our results is that a parallel, calcium-independent, second messenger pathway downstream of PLC mediates the synthesis and/or mobilization of endovanilloids involved in the PAR1-mediated modulation of sEPSC frequency.
What may be the identity of the endovanilloid released by astrocytes? Our experiments suggest that the likely candidate must fulfill at least two criteria: it should be produced in response to PLC activation and be able to gate TRPV1 receptors. Because PLC activation has been shown to generate anandamide (Liu et al. 2006 (Liu et al. , 2008 , which gates TRPV1 receptors (Ross, 2003) , our experiments are compatible with the hypothesis that anandamide (or a related endovanilloid) is the molecule involved.
The endocannabinoid system has been most extensively studied in neurons and several studies have shown that endocannabinoid release from neurons requires the activity of membrane transporters. Indeed, infusing postsynaptic cells with blockers of the EMT abolishes the endocannabinoid-dependent process of depolarizationinduced suppression of inhibition (Ronesi et al. 2004) . In our working model (Fig. 8) , the EMTs may be involved in the release of endovanilloids from astrocytes, in the uptake of endovanilloids into the presynaptic terminal, or both.
It is important to note that regardless of which cell type(s) express the EMTs, our result that OMDM1, a selective inhibitor of endovanilloid transport, prevents the effect of PAR1 activation on sEPSC suggests that the endovanilloids are not synthesized in the presynaptic terminal, since this should have a facilitating effect (or no effect) on the sEPSC potentiation (see Results). Importantly, our results suggest a new mechanistic interpretation of the previous observation that PAR1 activation elicits neuronal calcium elevation following an astrocytic calcium increase (Hermann et al. 2009 ). The authors reported that the neuronal calcium signal was eliminated by a cocktail of glutamate receptor blockers, while the astrocytic calcium signal was only slightly affected, and suggested that NTS astrocytes may release glutamate as a gliotransmitter in response to PAR1 activation. In a subsequent study (Vance et al. 2015) , the same group also reported that the PAR1 activation-dependent increase in neuronal calcium persisted, although reduced in amplitude, in conditions designed to reduce presynaptic glutamate release (500 nM TTX, 0.9 mM CaCl 2 and 6 mM MgCl 2 ) and concluded that astrocytes directly release glutamate onto postsynaptic neurons. This same study also showed that the glutamate released from astrocytes may also act on presynaptic terminals to potentiate glutamate release. Our results suggest that PAR1-mediated increase in somatic intracellular calcium in astrocytes is not necessary for the observed increase in excitatory neurotransmission and that a significant portion of the observed neuronal excitation is due to facilitation of TRPV1-dependent glutamate release from presynaptic terminals. This is in agreement with the observation that TRPV1-mediated glutamate release in the NTS is in part independent of presynaptic action potentials and directly activated by calcium influx through basal activation of TRPV1 channels . Thus, the relatively small effect on neuronal calcium level under synaptic blockade conditions reported by Vance et al. (2015) is indeed expected according to our model. While we do not rule out that glia also release glutamate as gliotransmitter, our data suggest that activation of presynaptic TRPV1 via endovanilloid release from glia constitutes the main mechanism for PAR1-mediated modulation of breathing in rats. On the other hand, direct glutamate release from astrocytes (Hermann et al. 2009 ) may mediate the TRPV1-independent, PAR1-mediated, neuronal activation. Thus these two mechanisms may both be important in the NTS, and possibly modulate diverse physiological functions.
Participation of astrocytes in synaptic signalling is now established (Fields & Stevens-Graham, 2002; Araque et al. 2014) ; however this function has generally been considered to critically depend on an increase in astrocytic intracellular calcium with release of glutamate as the gliotransmitter (Fellin & Carmignoto, 2004) . Here we describe an alternative signalling pathway that is independent of both astrocytic glutamate release and intracellular calcium levels. Thus, NTS astrocytes may have at least three independent signalling mechanisms all capable of modulating, either directly or indirectly, neuronal function. First, as in many other CNS areas (Perea et al. 2009; Araque et al. 2014 ), NTS astrocytes may be able to release glutamate in response to intracellular calcium elevation. Second, they modulate glutamate uptake in response to changes in their membrane potential, for example following metabolic stimuli such as small, physiological changes in extracellular pH (Huda et al. 2013) . Third, they regulate synaptic function by releasing endovanilloids that act on presynaptic TRPV1 receptors (this paper). Thus, NTS astrocytes fine-tune synaptic function through multiple pathways that are largely independent of each other, showing a degree of sophistication that greatly exceeds the prevalent idea of glia-neuron crosstalk. Future studies will show whether this elaborate interplay is limited to brainstem areas that, such as the NTS, are involved in the regulation of multiple systems (e.g. breathing, arterial pressure, heart rate, energy balance) or apply also to other brain areas. In this context, it is important to keep in mind that TRPV1 expression in the brain is sparse (Cavanaugh et al. 2011 ) and thus the pathway described here may represent a mechanism by which NTS astrocytes modulate synaptic transmission at select synapses.
Functional consequences of NTS PAR1 activation
Activation of the PAR1 receptor triggered signalling in the NTS has two distinct functional effects depending on the resolution of the experiments. At a cellular level, NTS neurons are activated due to the increased frequency of excitatory synaptic inputs. This is shown by the electrophysiological recordings performed in acute slices as well as by the cFOS production induced by direct injection of the PAR1 agonist peptide SFLLRN into the NTS of anaesthetized rats. In anaesthetized animals, however, the net effect is depression of breathing due to decreased peak amplitude of the integrated phrenic nerve output. The most conservative explanation of this finding is that the projections from the PAR1 activated NTS neurons to the rVRG contact inhibitory neurons, possibly GABAergic, proprio-bulbar neurons (Okazaki et al. 2001 ). Alternatively, it is possible that PAR1-activated neurons are themselves inhibitory. Our anatomical tracing experiments show a relatively large overlap between NTS cells that produce cFOS in response to PAR1 activation and retrograde labelling from the rVRG, suggesting that the observed modulation of breathing may not require projections to other areas. Independent of the possible network organization of PAR1-activated NTS neurons, we found that activation of PAR1 receptors in TRPV1 −/− rats did not affect breathing, confirming that the NTS response to SFLLRN requires TRPV1 channels in order to modulate breathing. A final consideration concerns the mechanism of PAR1 receptor activation in vivo. While several papers suggested that thrombin may activate brain PAR1 receptors in pathological conditions (Traynelis & Trejo, 2007) , the identity of the endogenous agonists in physiological conditions remains unclear. Nagai et al. (2008) suggested that the tissue plasminogen activator-plasmin system may play such role in physiological conditions. However, independently of the specific mechanism, the idea that brain PAR1 receptors are activated in physiological conditions is strongly supported by findings obtained with PAR1 −/− mice showing" that these animals have memory deficits (Almonte et al. 2013) . Whether the mechanisms of NTS PAR1 receptor activation in physiological conditions are the same as in other brain areas remains to be investigated.
